AR031834A1 - Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli - Google Patents
Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoliInfo
- Publication number
- AR031834A1 AR031834A1 ARP000105495A ARP000105495A AR031834A1 AR 031834 A1 AR031834 A1 AR 031834A1 AR P000105495 A ARP000105495 A AR P000105495A AR P000105495 A ARP000105495 A AR P000105495A AR 031834 A1 AR031834 A1 AR 031834A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- polyglycolized
- procedures
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion farmacéutica adecuada para su administracion por vía oral que comprende un derivado de camptotecina, una matriz de vehículo farmacéuticamente aceptable que es un glicérido poliglicolizado y, por lo menos, un excipiente farmacéuticamente aceptable seleccionado entre una lecitina, un fosfolípido, un aceite farmacéuticamente aceptable, un polietilenglicol y un mono-, di- o tri-glicérido saturado o insaturado. Procedimientos para preparar la composicion, una formulacion oral que comprende a la composicion farmacéutica y el uso de un derivado de la camptotecina, de un glicérido poliglicolizado y de un excipiente farmacéuticamente aceptable seleccionado entre una lecitina, un fosfolípido, un aceite farmacéuticamente aceptable, un polietilenglicol o un mono-, di- o triglicérido. La composicion farmacéutica puede administrarse a un mamífero, e inclusive a un ser humano, que pueda necesitar los efectos beneficiosos de la formulacion de un derivado de camptotecina. En consecuencia, las cápsulas pueden ser utilizadas para efectuar el tratamiento de una gran variedad de tipos de cáncer diferentes entre los que se incluyen, de manera no taxativa, los cánceres humanos de colon, mamas, pulmon, prostata, melanoma, páncreas, hígado, estomago, cerebro, rinon, utero, cuello del utero, ovarios y tracto urinario. Preferentemente, en los casos en los que la cápsula comprende CPT-11, esta cápsula se puede utilizar para el tratamiento del cáncer de colon y, en particular, del cáncer colorrectal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9925127.4A GB9925127D0 (en) | 1999-10-22 | 1999-10-22 | Oral formulations for anti-tumor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031834A1 true AR031834A1 (es) | 2003-10-08 |
Family
ID=10863264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105495A AR031834A1 (es) | 1999-10-22 | 2000-10-19 | Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli |
Country Status (26)
Country | Link |
---|---|
US (1) | US7201913B1 (es) |
EP (1) | EP1223936A1 (es) |
JP (1) | JP2003512430A (es) |
KR (1) | KR100838097B1 (es) |
CN (1) | CN1198616C (es) |
AR (1) | AR031834A1 (es) |
AU (1) | AU784201B2 (es) |
BR (1) | BR0014902A (es) |
CA (1) | CA2387648A1 (es) |
CO (1) | CO5251471A1 (es) |
CZ (1) | CZ20021372A3 (es) |
EA (1) | EA008284B1 (es) |
GB (1) | GB9925127D0 (es) |
HK (1) | HK1048253B (es) |
HU (1) | HUP0202850A3 (es) |
IL (2) | IL149044A0 (es) |
MX (1) | MXPA02003904A (es) |
MY (1) | MY138106A (es) |
NO (1) | NO322782B1 (es) |
NZ (1) | NZ518398A (es) |
PE (1) | PE20010809A1 (es) |
PL (1) | PL356236A1 (es) |
SK (1) | SK5102002A3 (es) |
TW (1) | TWI233355B (es) |
WO (1) | WO2001030351A1 (es) |
ZA (1) | ZA200203042B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062235A2 (en) * | 2000-02-28 | 2001-08-30 | Aventis Pharma S.A. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
US20070053869A1 (en) * | 2005-09-02 | 2007-03-08 | Yuichi Sugiyama | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8541459B2 (en) | 2007-01-26 | 2013-09-24 | Pola Pharma Inc. | Pharmaceutical composition |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
JP2011511071A (ja) * | 2008-02-08 | 2011-04-07 | ポニアード ファーマシューティカルズ, インコーポレイテッド | 肺癌を治療するためのピコプラチンおよびアムルビシン |
HUP0900614A2 (en) * | 2009-09-29 | 2011-05-30 | Mate Dr Hidvegi | Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production |
JP2013512948A (ja) * | 2009-12-08 | 2013-04-18 | イル・ファ・カンパニー・リミテッド | 20−O−β−D−グルコピラノシル−20(S)−プロトパナキサジオールを含む固体分散体 |
US9149533B2 (en) | 2013-02-05 | 2015-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10143657B2 (en) | 2014-01-17 | 2018-12-04 | Oncoral Pharma Aps | Solid oral dosage form of irinotecan for the treatment of cancer |
CN110448533B (zh) * | 2014-12-05 | 2022-03-29 | 天津键凯科技有限公司 | 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法 |
KR102293907B1 (ko) | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
KR102185475B1 (ko) | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2031803C (en) * | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5433951A (en) | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
IL115099A (en) * | 1994-10-14 | 1999-04-11 | Upjohn Co | Lyophilizate of phospholipid complex of water insoluble camptothecins |
IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
US5954998A (en) * | 1995-05-25 | 1999-09-21 | The Clorox Company | Liquid peracid precursor colloidal dispersions: oil-core vesicles |
EP1014953B1 (en) * | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
GB9711962D0 (en) * | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
DK0999838T3 (da) * | 1997-07-29 | 2002-07-08 | Upjohn Co | Selv-emulgerende formulering for lipofile forbindelser |
AR013261A1 (es) * | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
WO2000069434A1 (en) * | 1999-05-17 | 2000-11-23 | Ilex Oncology, Inc. | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
GB9918885D0 (en) * | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
-
1999
- 1999-10-22 GB GBGB9925127.4A patent/GB9925127D0/en not_active Ceased
-
2000
- 2000-10-02 BR BR0014902-0A patent/BR0014902A/pt not_active Application Discontinuation
- 2000-10-02 KR KR1020027005068A patent/KR100838097B1/ko not_active IP Right Cessation
- 2000-10-02 EP EP00966102A patent/EP1223936A1/en not_active Withdrawn
- 2000-10-02 EA EA200200480A patent/EA008284B1/ru not_active IP Right Cessation
- 2000-10-02 CZ CZ20021372A patent/CZ20021372A3/cs unknown
- 2000-10-02 CN CNB008146594A patent/CN1198616C/zh not_active Expired - Fee Related
- 2000-10-02 PL PL00356236A patent/PL356236A1/xx not_active IP Right Cessation
- 2000-10-02 SK SK510-2002A patent/SK5102002A3/sk unknown
- 2000-10-02 HU HU0202850A patent/HUP0202850A3/hu unknown
- 2000-10-02 MX MXPA02003904A patent/MXPA02003904A/es active IP Right Grant
- 2000-10-02 CA CA002387648A patent/CA2387648A1/en not_active Abandoned
- 2000-10-02 NZ NZ518398A patent/NZ518398A/en unknown
- 2000-10-02 US US10/110,225 patent/US7201913B1/en not_active Expired - Fee Related
- 2000-10-02 WO PCT/EP2000/009647 patent/WO2001030351A1/en active IP Right Grant
- 2000-10-02 IL IL14904400A patent/IL149044A0/xx active IP Right Grant
- 2000-10-02 AU AU76613/00A patent/AU784201B2/en not_active Ceased
- 2000-10-02 JP JP2001532771A patent/JP2003512430A/ja not_active Withdrawn
- 2000-10-07 TW TW089121016A patent/TWI233355B/zh not_active IP Right Cessation
- 2000-10-19 MY MYPI20004934A patent/MY138106A/en unknown
- 2000-10-19 AR ARP000105495A patent/AR031834A1/es unknown
- 2000-10-19 PE PE2000001113A patent/PE20010809A1/es not_active Application Discontinuation
- 2000-10-19 CO CO00079673A patent/CO5251471A1/es not_active Application Discontinuation
-
2002
- 2002-04-09 IL IL149044A patent/IL149044A/en not_active IP Right Cessation
- 2002-04-17 ZA ZA200203042A patent/ZA200203042B/en unknown
- 2002-04-18 NO NO20021834A patent/NO322782B1/no unknown
-
2003
- 2003-01-15 HK HK03100370.7A patent/HK1048253B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU784201B2 (en) | 2006-02-23 |
US7201913B1 (en) | 2007-04-10 |
SK5102002A3 (en) | 2002-11-06 |
IL149044A (en) | 2007-03-08 |
NO20021834L (no) | 2002-04-18 |
CO5251471A1 (es) | 2003-02-28 |
NO322782B1 (no) | 2006-12-11 |
IL149044A0 (en) | 2002-11-10 |
EA008284B1 (ru) | 2007-04-27 |
CN1198616C (zh) | 2005-04-27 |
CA2387648A1 (en) | 2001-05-03 |
ZA200203042B (en) | 2003-04-17 |
GB9925127D0 (en) | 1999-12-22 |
NO20021834D0 (no) | 2002-04-18 |
MXPA02003904A (es) | 2003-07-14 |
HK1048253A1 (en) | 2003-03-28 |
KR20020045613A (ko) | 2002-06-19 |
HUP0202850A3 (en) | 2004-12-28 |
HK1048253B (zh) | 2005-12-02 |
CN1382050A (zh) | 2002-11-27 |
KR100838097B1 (ko) | 2008-06-13 |
TWI233355B (en) | 2005-06-01 |
JP2003512430A (ja) | 2003-04-02 |
PL356236A1 (en) | 2004-06-28 |
NZ518398A (en) | 2004-01-30 |
EP1223936A1 (en) | 2002-07-24 |
PE20010809A1 (es) | 2001-08-01 |
BR0014902A (pt) | 2002-06-11 |
AU7661300A (en) | 2001-05-08 |
HUP0202850A2 (hu) | 2003-01-28 |
MY138106A (en) | 2009-04-30 |
CZ20021372A3 (cs) | 2002-09-11 |
WO2001030351A1 (en) | 2001-05-03 |
EA200200480A1 (ru) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031834A1 (es) | Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli | |
ES2978534T3 (es) | Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer | |
NO863620D0 (no) | Fremgangsmaate for fremstilling av et farmasoeytisk preparat | |
ES2244098T3 (es) | Un conjugado covalente de clozapina con un acido graso y su uso para tratar la esquizofrenia. | |
WO2004017940A3 (en) | Pharmaceutically active lipid based formulation of sn38 | |
AR029084A1 (es) | Composiciones y metodos para el tratamiento del cancer | |
DK0491778T3 (da) | Indretning til administration af medikamenter til slimhindevæv. | |
DE69531701D1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
CO5570677A2 (es) | Quinolinilpirrolopirazoles | |
ES2090395T3 (es) | Formulados farmaceuticos gastroresistentes para administracion por via oral que contienen acidos biliares. | |
ES2727686T3 (es) | Tratamiento de enfermedades que implican mucina | |
BR0010082A (pt) | Método para melhorar a eficácia de um agente antitumoral | |
AR018166A1 (es) | Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos | |
ES2746105T3 (es) | Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer | |
AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
KR20100031759A (ko) | 흑색종의 치료 | |
PE20010407A1 (es) | Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa | |
ES2243328T7 (es) | Preparado farmaceutico que contiene agentes citostaticos y aceptores de electrones para tratar cancer. | |
AR014640A1 (es) | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. | |
ES2567455T3 (es) | Nanoemulsiones que comprenden derivados de espicamicina para su uso en el tratamiento del dolor | |
MY166524A (en) | Therapeutic substance, pharmaceutical composition, helicobacter pylori growth inhibitor and method for conducting anti-helicobacter therapy | |
US4699776A (en) | Suppositories containing analgesics, antipyretics or anti-inflammatory agents | |
AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
ES2372056T3 (es) | Uso de 7-t-butoxiiminometilcamptotecina para tratar neoplasmas uterinos. | |
CN107519130A (zh) | 含有奎宁盐悬浊液的用于抗癌治疗的局部用药注射剂组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |